219 related articles for article (PubMed ID: 36547766)
1. Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery.
Tse B; Nisenbaum R; Floros G; Jiwajee A; Teitel J; Sholzberg M
J Thromb Thrombolysis; 2023 Feb; 55(2):273-281. PubMed ID: 36547766
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
Lehtinen AE; Baghaei F; Astermark J; Holme PA
Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
[TBL] [Abstract][Full Text] [Related]
3. Low-dose continuous infusion of factor VIII in patients with haemophilia A.
Prelog T; Dolničar MB; Kitanovski L
Blood Transfus; 2016 Sep; 14(5):474-80. PubMed ID: 26674820
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in surgery and its perioperative treatment in people with hemophilia.
Rodríguez-Merchán EC
Expert Rev Hematol; 2021 Mar; 14(3):271-280. PubMed ID: 33605827
[No Abstract] [Full Text] [Related]
6. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
[TBL] [Abstract][Full Text] [Related]
7. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
[TBL] [Abstract][Full Text] [Related]
8. Hemophilia in Iran.
Dorgalaleh A; Dadashizadeh G; Bamedi T
Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan.
Tu TC; Liou WS; Chou TY; Lin TK; Lee CF; Chen JD; Cham TM; Chung MI
Yonsei Med J; 2013 Jan; 54(1):71-80. PubMed ID: 23225801
[TBL] [Abstract][Full Text] [Related]
11. Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.
Park YS; Shin WJ; Kim KI
BMC Musculoskelet Disord; 2017 Aug; 18(1):356. PubMed ID: 28830476
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
[TBL] [Abstract][Full Text] [Related]
13. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K; Walker I; Decker K; Chan AK; Pai MK
Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
Quon DV; Logan L
Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I
Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114
[TBL] [Abstract][Full Text] [Related]
17. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
[TBL] [Abstract][Full Text] [Related]
18. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
19. [Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
Yamamoto M; Nakadate H; Iguchi U; Masuda H; Sakai H; Ishiguro A
Rinsho Ketsueki; 2013 Mar; 54(3):300-4. PubMed ID: 23676647
[TBL] [Abstract][Full Text] [Related]
20. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
